Characterization of very late dysphagia after chemoradiation for oropharyngeal squamous cell carcinoma.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
12 2020
Historique:
received: 21 04 2020
revised: 03 06 2020
accepted: 07 06 2020
pubmed: 18 8 2020
medline: 14 9 2021
entrez: 18 8 2020
Statut: ppublish

Résumé

Improved prognosis for p16+ oropharyngeal squamous cell carcinoma (OPSCC) has led to efforts to mitigate long-term complications of treatment, which remains poorly defined in late survivors. Here we characterize very late dysphagia in OPSCC. Long-term review of 93 p16+ OPSCC patients treated with chemoradiation was performed. We scored videofluoroscopic swallow studies (VFSS) according to the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) scale. Very late dysphagia was defined >2.5 years from end of treatment. Fine-Gray regression models were used to assess dysphagia with competing risk of death. Median follow up was 10.5 years. 402 total VFSS were assessed (median 4 per patient, range 0-8). 15.1% of patients had a DIGEST score ≥2 very late after treatment. Very late DIGEST score ≥2 correlated with T-stage (HR 1.7, p = 0.049), second cancer (HR 6.5, p = 0.004), superior pharyngeal constrictor dose (HR 1.11, p = 0.050), total tongue dose (HR 1.07, p = 0.045), but not hypoglossal nerve dose (p > 0.2). Seven patients (7.5%) had late progressive dysphagia, defined as DIGEST score that increased by ≥2 beyond one year after treatment, and this correlated with higher ipsilateral hypoglossal nerve D1cc dose (75 vs 72 Gy, p = 0.037). In p16+ OPSCC patients treated with definitive chemoradiation, at least 7.5% developed late progressive dysphagia, and 15.1% experienced moderate dysphagia >2.5 years from treatment. Our study suggests that dose to tongue musculature may be associated with very late dysphagia, and hypoglossal nerve dose may be associated with late progressive dysphagia. More intensive long-term dysphagia survivorship monitoring is suggested.

Identifiants

pubmed: 32805634
pii: S1368-8375(20)30289-X
doi: 10.1016/j.oraloncology.2020.104853
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

104853

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Laila A Gharzai (LA)

Department of Radiation Oncology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.

Pin Li (P)

Department of Biostatistics, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48109, USA.

Matthew J Schipper (MJ)

Department of Biostatistics, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48109, USA. Electronic address: mjschipp@med.umich.edu.

John Yao (J)

Department of Radiation Oncology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.

Charles S Mayo (CS)

Department of Radiation Oncology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.

Joel R Wilkie (JR)

Department of Radiation Oncology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.

Peter G Hawkins (PG)

Department of Radiation Oncology, The Permanente Medical Group, 5900 State Farm Dr, Rohnert Park, CA 94928, USA.

Teresa Lyden (T)

Department of Otolaryngology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.

Anna Blakely (A)

Department of Otolaryngology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.

Mohannad Ibrahim (M)

Department of Radiology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.

Caitlin A Schonewolf (CA)

Department of Radiation Oncology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.

Jennifer Shah (J)

Department of Radiation Oncology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.

Avraham Eisbruch (A)

Department of Radiation Oncology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.

Keith Casper (K)

Department of Otolaryngology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.

Michelle Mierzwa (M)

Department of Radiation Oncology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA. Electronic address: mmierzwa@med.umich.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH